<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568239</url>
  </required_header>
  <id_info>
    <org_study_id>ARVD-LAMRES</org_study_id>
    <nct_id>NCT04568239</nct_id>
  </id_info>
  <brief_title>Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)</brief_title>
  <acronym>LAMRES</acronym>
  <official_title>Impact of M184V on the Virological Efficacy to Lamivudine/Dolutegravir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association de Recherche en Virologie et Dermatologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association de Recherche en Virologie et Dermatologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In view of the prolongation of patients living with HIV's life expectancy, the question of&#xD;
      optimization of ART, which is still a life-long treatment, becomes central. While most&#xD;
      patients achieve virological success, their treatments often need to be optimized in order to&#xD;
      limit adverse events, drugs interactions and to improve adherence. The switch to dual regimen&#xD;
      strategies represent one of the approaches for treatment optimization. Indeed, dual therapy&#xD;
      regimens have shown non-inferior efficacy vs triple therapy as simplification therapy and&#xD;
      more recently also as first line therapy. From the real-life data it emerges that today in&#xD;
      simplification strategies, the dual regimen therapies are prescribed even in patients with a&#xD;
      history of virological failure. Circulating HIV-1 resistant variants can be archived in viral&#xD;
      reservoirs, where they can persist for years and can reemerge in case of therapeutic&#xD;
      selective pressure. In particular, previous selection of M184V may have an impact on&#xD;
      virological response to 3TC/DTG. There are few data on a direct comparison of 3TC/DTG&#xD;
      efficacy in patients harboring or not harboring the M184V. So, there is a need to assess the&#xD;
      efficacy of 3TC/DTG in patients with past M184V mutation in a large set of patients followed&#xD;
      in clinical setting.&#xD;
&#xD;
      Thus, the investigators propose a retrospective study of patients with HIV-RNA ≤50 copies/mL&#xD;
      who were switched to 3TC/DTG in order to compare the virological efficacy of 3TC/DTG in&#xD;
      patients with and without a history of M184V detection in a previous resistance genotype.&#xD;
      This study aimed to analyze 800 patients switched to DTG/3TC in clinical real setting in&#xD;
      large European (France, Italy, Spain) database.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>probability of virological failure</measure>
    <time_frame>12 months</time_frame>
    <description>probability of virological failure that is defined as HIV-RNA &gt;50 copies/mL in 2 consecutive determinations or ≥200 copies/mL in a single determination. This outcome will be evaluated overall and between the M184V- and M184V+ patients' groups.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>M184V + group and M184 - group</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-1-infected patients with (i) age ≥18 years, (ii) HIV-RNA ≤50 copies/mL on any ART&#xD;
        regimen, (iii) subsequently switching to DTG/3TC, (iv) with at least 1 previous plasma&#xD;
        HIV-1 RNA or HIV-DNA genotype, (v) with at least 1 virological and clinical follow-up after&#xD;
        switching to DTG/3TC.&#xD;
&#xD;
        The occurrence of M184V will be assessed using historical genotypic resistance tests; that&#xD;
        is, any detection of this mutation in any previous resistance test will be scored as&#xD;
        positive.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infected&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Switched to 3TC/DTG while having HIV-RNA ≤50 copies/mL on any ART regimen&#xD;
&#xD;
          -  Followed for at least 1 year after 3TC/DTG switch&#xD;
&#xD;
          -  With at least 1 previous genotype&#xD;
&#xD;
          -  With at least 1 virological follow-up after switching to 3TC/DTG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No genotypic resistance test available before switching to DTG/3TC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Genevieve Marcelin, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sorbonne University; APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Genevieve Marcelin, PharmD, PhD</last_name>
    <phone>+33142177401</phone>
    <email>anne-genevieve.marcelin@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eve Todesco, PharmD, PhD</last_name>
    <phone>+33142177401</phone>
    <email>eve.todesco@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ARVD</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Geneviève MARCELIN</last_name>
      <email>anne-genevieve.marcelin@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

